MRA General RFP

Click here to receive future RFPs

MRA 2021-2022 Request for Proposals - Now Closed

The Melanoma Research Alliance (MRA) is pleased to announce a Request for Proposals (RFP) for pre-clinical, translational, and early clinical research with the potential to produce unusually high impact, near-term advancements in melanoma prevention, detection, diagnosis, staging, and treatment.

The 2021 - 2022 award cycle, is anticipated to support at least $12.8 million in new funding. Proposals will be accepted for Team Science, Academic-Industry Partnership, Young Investigator, and Pilot Awards. 

Special Opportunities Included in RFP:

  • MRA Young Investigator, Pilot, and Team Science Awards for Women in Melanoma Research
  • Immunotherapy Young Investigator Awards supported by Bristol Myers Squibb (BMS)
  • New in Second Release (8/30): Two Team Science Awards - each $1.5 million over 5 years -  focused on patient-centric clinical trials, jointly funded by The Rising Tide Foundation for Clinical Cancer Research (RTFCCR) and MRA. Patient engagement must be actively demonstrated throughout the full life cycle of the clinical trial, including planning and dissemination. For more information, about how to effectively engage patients in guiding research, please watch this video. Specific guidance for preparing a Patient-centric Research Plan can be found here.

Please note the following key deadlines:

  • October 6: Team Science Award Letters of Intent Due
  • November 3: Young Investigator Award Eligibility Checklist Due to rfischer@curemelanoma.org.
  • November 17: Young Investigator and Pilot Awards Full Proposals Due
  • January 19: Team Science Award Full Proposals Due (from invited applicants)

All proposals are due by 11:59 pm Eastern Time. Proposals should be submitted via the proposalCENTRAL on-line application tool: https://proposalcentral.com/.

MRA 2021 - 2022 Request for Proposal Second Release

MRA Award Terms and Conditions 

MRA accepts proposals from researchers worldwide and encourages applications from a diverse pool of investigators with respect to race, gender, sexual orientation, ethnicity, national origin, country of residence, and disability. MRA recognizes that diversity in the biomedical research workforce is critical for ensuring that the most creative minds have the opportunity to contribute to realizing our research goals and to ensuring more equitable health outcomes for all.


Questions: 

Rachel Fischer - Senior Associate, Scientific Program and Grants Administration: rfischer@curemelanoma.org

Login

×